A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)

NCT00239655 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG: MK0812

Sponsor

Merck Sharp & Dohme LLC